Jci_page_head_homepage_01 Jci_page_head_homepage_02
Ted M. Dawson, Valina L. Dawson
Published in Volume 111, Issue 2
J Clin Invest. 2003; 111(2):145–151 doi:10.1172/JCI17575
Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

Structure of α-synuclein and a model of α-synuclein aggregation and toxicity. The modular structure of α-synuclein, illustrating the location of familial-associated mutations and other key features of α-synuclein, including the imperfect (KTKEGV) repeats (R), is depicted in the top panel. The bottom panel shows a model of α-synuclein aggregation and toxicity and the proposed factors that enhance (+) or inhibit (–) the formation of toxic aggregated forms of α-synuclein. DA enhances the formation of the protofibrillar form of α-synuclein and prevents it from aggregating into the fibrillar form (not shown).